Registration for the 3rd Alzheimer's-Focused #C4CT Summit Has Closed Due to Overwhelming Interest
July 30 2014 - 8:00AM
Brewer Sports International (BSI), a multi-faceted global sports
advisory firm, and Amarantus BioScience Holdings, Inc.
(OTCQB:AMBS), a biotechnology company focused on the discovery and
development of novel diagnostics and therapeutics related to cell
cycle dysregulation, endoplasmic reticulum stress,
neurodegeneration and apoptosis, today announced that due to
overwhelming registration for the upcoming #C4CT Summit to be held
at the United Nations on July 31st, 2014, the Coalition for
Concussion Treatment is reluctantly unable to accept any new
registrants. This summit will be the largest to date with hundreds
of confirmed guests including doctors and medical researchers
specializing in the treatment of neurodegenerative diseases, policy
makers, international ambassadors, athletes and victims of
traumatic brain injury (TBI). The summit will cover Alzheimer's
disease and other neurodegenerative diseases and the emerging link
between traumatic brain injury and neurological conditions.
The recent announcement of panelists including Dr.
Thomas Arendt, Managing Director of the Paul Flechsig
Institute of Brain Research, Leipzig University and Director of the
Alzheimer Centre Leipzig, The Honorable James
Greenwood, President and CEO of the Biotechnology Industry
Organization (BIO), Andrew Brandt, NFL analysts
for ESPN and Andrea Kremer, Chief Correspondent
for Player Health and Safety at the NFL Network have contributed to
demand leading up to the conference. Additional key speakers
include The Honorable Chaka Fattah (D-PA),
Dr. Robert Cantu and Dr. Robert
Stern. For a complete list of speakers please visit
www.c4ctsummit.com.
A live stream of this event will be available at webtv.un.org,
and a direct link to the webcast will be made available at
www.c4ctsummit.com the morning of the event.
Sponsorship opportunities are still available. For information
please visit: www.c4ctsummit.com/sponsorship-opportunities.
#C4CT MISSION
The Coalition for Concussion Treatment (#C4CT) serves as a
platform to spread awareness about concussions and the severe
effects of Traumatic Brain Injury (TBI). Through a global campaign
uniting people who are passionate about the cause, #C4CT fosters
the critical discussions and partnerships needed to enhance
research, treatment efforts and prevention. The overall goal of the
coalition is to continue building awareness of key scientific and
medical advances in an ongoing effort to identify and develop new
TBI treatment opportunities.
#C4CT CONCUSSION AWARENESS SUMMIT
Thursday, July 31, 2014
United Nations, New York City
Door open at 8:30 am // Summit starts at 9:00 am
Presented By: Amarantus Bioscience Holdings and Brewer Sports
International
Powered By: MDM Worldwide
Topics Include: The Current State of Sports Concussions, TBI and
the Potential Link to Alzheimer's disease, Alzheimer's Research and
Potential Treatments, Funding and Public Policy, Current and Former
Professional Athletes' Personal Stories
More Info on: www.c4ctsummit.com
Share your support for #C4CT on Twitter!
About #C4CT
The Coalition for Concussion Treatment (#C4CT) was founded in
2012 by former NFL player Jack Brewer, CEO of Brewer Sports
International and Gerald Commissiong, President and CEO at
Amarantus BioScience Holdings, Inc. with the goal of bringing
together those who are directly affected by TBI-induced
neurodegenerative diseases with world class researchers,
scientists, and industry leaders whom are actively working towards
identifying and developing innovative TBI treatment opportunities.
#C4CT serves as a platform to spread awareness about concussions
and the severe effects of Traumatic Brain Injury (TBI). #C4CT
fosters the critical discussions and partnerships needed to enhance
research, treatment efforts, and prevention through a global
campaign uniting people who are passionate about the
cause.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company
developing treatments and diagnostics for diseases associated with
neurodegeneration and protein misfolding-related apoptosis. AMBS
has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready small
molecule indicated for Parkinson's Levodopa induced dyskinesia and
Adult ADHD. AMBS has an exclusive worldwide license to the
Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's
disease and owns the intellectual property rights to a therapeutic
protein known as Mesencephalic-Astrocyte-derived Neurotrophic
Factor ("MANF") and is developing MANF-based products as treatments
for brain disorders. AMBS also owns intellectual property for the
diagnosis of Parkinson's disease ("NuroPro") and the discovery of
neurotrophic factors ("PhenoGuard"). Amarantus operations are
located at Janssen Labs @QB3 in San Francisco, CA. For further
information please visit www.Amarantus.com, or connect with the
Company on Facebook, LinkedIn, Twitter and Google+.
About Brewer Sports International
Founded by international entrepreneur Jack Brewer, five-year
National Football League (NFL) veteran and former three-team
captain, Brewer Sports International (BSI) is a multi-faceted
global sports advisory firm within The Brewer Group Companies with
a focus on the business of sport and wellness for professional
athletes, sports agencies, public and private corporations and
various partners including international organizations, governments
and NGOs. Based in Minneapolis with offices spanning the globe, BSI
offers a unique financial services platform to professional
athletes and sports agencies, as well as high-net-worth individuals
and businesses related to sports. BSI takes pride in enabling its
clients to capitalize on the endless opportunities presented
through sport. For more information, please visit
www.brewersports.com or follow them on Facebook, Twitter and
LinkedIn.
About MDM Worldwide
MDM Worldwide Solutions, Inc. is a digital communications agency
that develops and manages online engagement strategies to connect
companies with their stakeholders. MDM specializes in working with
clients in the technology, healthcare and life sciences spaces.
MDM's vast industry knowledge, proprietary methodology, proven
track record and experienced leadership team enables them to create
and customize targeted digital marketing campaigns to fulfill all
of their clients' objectives. For more information, please visit
mdmworldwide.com or find them
on Facebook, Twitter, Google+ and LinkedIn.
CONTACT: Amarantus Bioscience Holdings, Inc.:
Aimee Boutcher, Director of Investor Relations
408.737.2734 x 101
ir@amarantus.com
Brewer Sports International:
Kristi Hofacker, Director of Interactive Marketing & Media
The Brewer Group, Inc.
kristi.hofacker@thebrewergroup.com
651.247.4460
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2023 to Apr 2024